Regenera sees new applications for technology
04 August, 2004 by Melissa TrudingerRegenera (ASX:RGA) has picked up three new applications for ocular applications of its core product Visagen, a proprietary formulation of synthetic steroid triamcinolone acetonide.
Regenera set to begin Singapore trials
03 August, 2004 by Melissa TrudingerRegenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.
FDA OK's higher dose of Starpharma's VivaGel
03 August, 2004 by Melissa TrudingerStarpharma (ASX: SPL) will move to the next stage of the Phase I clinical trial for its nanodendrimer-based vaginal microbicide VivaGel, after the US FDA approved a dose increase based on the interim trial results.
Biotech IPOs continue to provide excellent returns
02 August, 2004 by Michael VitaleInvestors in the initial public offerings (IPOs) of Australian biotechnology companies have done well over the past six years -- despite the fact that the shares of most of the newly listed companies are currently trading below the price at which they were first sold.
Meditech announces new CEO, chairman
02 August, 2004 by Melissa TrudingerMeditech Research (ASX: MTR) has appointed former CSL and Millennium Pharmaceuticals executive Dr Ian Nisbet as CEO to replace Chris Carter who stepped down on Friday, after a shareholder stoush in April forced his resignation.
Chemeq plant finally operational
02 August, 2004 by Renate KrelleProduction facilities at Chemeq (ASX:CMQ) have finally come to life, with the company announcing that it has manufactured enough of the active pharmaceutical ingredient of its novel antimicrobial to verify the production process.
OGTR backs Hexima field trial
02 August, 2004 by Graeme O'NeillMelbourne-based agbiotech company Hexima will make a small piece of biotech history in October by becoming the first homegrown Victorian company to trial a genetically modified field crop.
Pharmaxis on a roll
30 July, 2004 by Graeme O'NeillSydney pharmaceutical company Pharmaxis (ASX:PXS) has completed enrolling 600 asthma patients for a phase III trial of its patented asthma prognostic, Aridol.
Meditech CEO leaves, chair steps down
30 July, 2004 by Melissa TrudingerMeditech (ASX: MTR) is looking for a new CEO as CEO Chris Carter steps down, three months after a shareholder stoush forced his resignation from the company.
Benitec burning cash, looking for licenses
29 July, 2004 by Renate KrelleBrisbane-based Benitec (ASX: BLT) has announced a loss of AUD$1.9 million for the quarter, and confirmed that it has just $4.65 million remaining in cash.
Prima's CancerVac begins ovarian cancer trial
29 July, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) subsidiary CancerVac began a Phase IIa clinical trial today to evaluate its immunotherapy in patients with ovarian cancer.
Elastagen stretches commercial wings
29 July, 2004 by Graeme O'NeillNew Sydney University spinoff Elastagen is courting potential investors and commercial collaborators to develop organ-and-tissue-engineering applications for its super-stretchy protein, tropoelastin.
Peplin lead molecule active against leukaemia
28 July, 2004 by Renate KrellePeplin Biotech (ASX:PEP) has claimed its lead molecule PEP005 has shown highly selective activity against acute myelogenous leukaemia (AML) in pre-clinical studies.
Biotechs benefit from ARC grant round
28 July, 2004 by Renate KrelleSeveral Australian biotechs, including Novogen, Proteome Systems, Starpharma and Ventracor, were winners in the second round of Australian Research Council (ARC) linkage grants, announced earlier this month.
Polartechnics quadruples sales, but J&J drops TruScreen
28 July, 2004 by Renate KrelleSydney-based devices company Polartechnics (ASX:PLT) today announced its product-sales revenue had increased four-fold to AUD$2.14 million for the financial year ended June 30 2004.
